中国临床心理学杂志

不同年代住院精神分裂症患者药物治疗情况调查

作者：张丽珠程灶火

分类号：R395.2

出版年,卷(期):页码：2013,21(2):248-250

摘要：

目的:了解住院精神分裂症患者药物治疗情况的年代变迁。方法:采用回顾性研究设计,从三所精神卫生专科医院分层随机抽取不同年代住院精神分裂症患者的病历资料,登记药物治疗情况和相关资料。结果:不同年代间单一用药比例无显著改变(P<0.05),但联合用药方案有显著差异(P<0.01),其中1980年代以FGA+FGA联用为主,1990年代以SGA+FGA联用为主,2000年代以SGA+FGA和SGA+SGA为主;不同年代间合并用药种类存在显著差异(P<0.05),抗胆碱能药逐渐减少,抗焦虑药和抗惊厥药逐渐增加;不同年代间稳定治疗剂量无显著差异(P>0.05)、时点最高剂量存在差异(P<0.05)。结论:联合用药和合并用药方式发生了显著改变,非典型抗精神病药物使用频率和合并使用抗焦虑和抗惊厥药物频率呈递增趋势,最高用药剂量呈下降趋势。

Objective: To investigate changes of drug treatments for schizophrenic inpatients across decades. Methods: According to retrospective research designs, the medical records of schizophrenic inpatients in different years were selected from three mental hospitals with stratified random sampling method, then recorded the drug treatment and related information. Results: There was no statistically significant difference (P>0.05) on the antipsychotic mono-therapy rate across decades, but the antipsychotic combination pattern was significantly different (P<0.05) across decades. Most common antipsychotic polypharmacy was FGAs+SGAs in 1980ss, FGAs+SGAs in 1990ss, FGAs+SGAs and SGAs+SGAs in 2000s. Moreover, there was statistically significant difference (P<0.05) on the comedication pattern, anti-cholinergic drug was decreased, and anti-anxiety agent and anticonvulsant were increased by years. In addition, there was no statistically significant difference (P>0.05) for the stable therapeutic dosage, and there was significant difference for the highest time dosage (P<0.05) across years. Conclusion: The antipsychotic polypharmacy and comedication pattern have changed over the last three decades, at the same time, the using rates of SGAs, antianxiety agents and anticonvulsants are increasing, and the highest time dose is declining.

基金项目：

作者简介：

参考文献：

1 司天梅, 舒良, 于欣, 等. 10 省市抗精神病药使用现状的调查. 中华精神科杂志, 2004, 37(3): 153—155
2 Ganguly R, Kotzan JA, Miller LS, et al. Prevalence, trends,and factors associated with antipsychotic polypharmacy among Medicaid-eligible schizophrenia patients, 1998-2000.Journal of Clinical Psychiatry, 2004, 65(10): 1377-88
3 Clark RE, Bartels SJ, Mellman TA, et al. Recent trends inantipsychotic combination therapy of schizophrenia andschizoaffective disorder: Implications for state mental healthpolicy. Schizophrenia Bulletin, 2002, 28: 75-84
4 张云淑, 司天梅, 栗克清. 中国十省市第一代及第二代抗精神病药使用现况调查.中国心理卫生杂志,2012, 26(10): 736-740
5 Gallego JA, Bonetti J, Zhang J, et al. Prevalence and correlates of antipsychotic polypharmacy: A systematic reviewand meta-regression of global and regional trends from the1970s to 2009. Schizophrenia Research, 2012, 138(1): 18-28
6 任峰, 王涌, 姚贵忠, 等. 住院精神分裂症患者苯海索的使用情况及相关因素. 中国心理卫生杂志, 2012, 26(3): 199-203
7 龙森. 住院精神分裂症患者给药方案时点调查. 药物流行病学杂志, 2010, 19(5): 279-281
8 Zink M, Englisch S, Meyer-Lindenberg A. Polypharmacy inschizophrenia. Current Opinion in Psychiatry, 2010, 23:103-111
9 Paton C, Lelliott P, Harrington M, et al. Patterns of antipsychotic and anti -cholinergic prescribing for hospital inpa tients. Journal of Psychopharmacology, 2003, 17: 223-229
10 Elie D, Poirier M, Chianetta JM, et al. Cognitive effects ofantipsychotic dosage and polypharmacy: A study with theBACS in patients with the BACS in patients with schizophrenia and schizoaffective disorder. Journal of Psychophar macology, 2010, 24(7): 1037-1044

服务与反馈：

【文章下载】【加入收藏】